Integrating Immune Checkpoint Inhibitors Into Earlier Stages of Bladder Cancer

In this activity, a panel of experts with experience managing bladder cancer evaluate the evidence for the use of immune checkpoint inhibition in earlier stages of bladder cancer, as well as explore strategies for monitoring treatment response and managing immune-mediated adverse events. For the complete activity, including supporting material, please visit: www.peervoice.com/SDC861. Presented by: Syed Hussain, MBBS, MD, FRCP, Diane Leach, MSc, ACP, RGN, and Brenda Martone, MSN, ANP-BC, AOCNP. Learning Objectives: Recall the results of clinical trials assessing the safety and efficacy of immune checkpoint inhibitor therapy in the management of muscle-invasive and non-muscle invasive bladder cancer; Implement recommended procedures for the handling and administration of immune checkpoint inhibitors in patients with bladder cancer; and Formulate appropriate adverse event monitoring and management plans for patients receiving perioperative immunotherapy, including patient education approaches, timely identification of an immune-mediated adverse event, and appropriate dose adjustment where an immune-mediated adverse event occurs.